Hispanic Patients With Pediatric Neuroblastoma May Have Worse OS Outcomes vs Other Ethnic Subgroups


Non-White Hispanic pediatric patients with neuroblastoma appear to have worse overall survival outcomes vs other patient subgroups.

Investigators reported inferior survival in non-White Hispanic pediatric patients with neuroblastoma vs other patient subgroups, according to an analysis of data from Children’s Oncology Group (COG) trials that was presented at a press briefing ahead of the 2022 American Society of Clinical Oncology Annual Meeting.1,2

Lead author Puja J. Umaretiya, MD, a clinical fellow in pediatric hematology/oncology at Dana-Farber Cancer Institute and Boston Children's Hospital, in Massachusetts said that the results suggest that equal access to care does not necessarily translate into equitable outcomes.

“Our data show that Hispanic children with high-risk neuroblastoma have inferior OS compared with other children,” she said. “This is despite having access to the same clinical trials and receiving the same uniform plan treatment and after controlling for disease associated factors.

“We acknowledge that describing disparities is simply not enough, we must strive to identify mechanisms that cause inequitable outcomes,” she said. “And in this cohort, we begin to do so by looking at things like stopping a trial, early delays in therapy, or increased rates of relapse, none of which seem to explain the survival differences that we see by race and ethnicity.”

In multivariate models, the 5-year OS was approximately 47% for Hispanic children compared with 50% for other non-Hispanic children, 61% for white non-Hispanic children, and 63% for Black non-Hispanic children (P = .047).

Umaretiya said that existing data have shown that Black children with neuroblastoma are more likely to experience late relapse. Furthermore, children with public insurance, a proxy for household poverty, are more likely to relapse and more likely to die when treated on immunotherapy trials.

The causes for these disparities are unknown. Investigators felt that a clinical trial was the ideal setting to explore the question because care is highly standardized. They sought to identify the associations between survival and race, ethnicity, and socioeconomic status. Investigators also wanted to explore associations between those factors and possible mechanisms for poorer survival like early trial discontinuation, delays in induction chemotherapy, and relapsed disease.

Umaretiya and her team conducted a retrospective cohort study on data from children (N = 669) with high-risk neuroblastoma treated in 3 upfront COG trials from 2007 to 2016: ANBL0532 (NCT00567567) evaluating 2 high-dose chemotherapy regimens followed by a stem cell transplant, ANBL0P1 (NCT01175356) evaluating induction therapy followed by meta-iodobenzylguanidine labeled with iodine-131 and chemotherapy in treating patients undergoing stem cell transplant, radiation therapy, and maintenance therapy with isotretinoin; and ANBL12P1 (NCT01798004) evaluating busulfan, melphalan, and stem cell transplant following chemotherapy.

Five-year OS was lower among children who used only public insurance compared to others (53% vs 63%) and among children living in neighborhood level poverty compared to others (54% vs 62%). However, Umaretiya added that proxy poverty measures did not remain significantly associated with survival after adjusting for other factors including race, ethnicity, and disease-associated factors.

“We looked at mean duration of induction by days and found that overall, by race and ethnicity, there were no significant differences. We also found that there was no difference in who stopped trial participation early by race and ethnicity,” she said. “A little over one-third of patients stopped the trial early, regardless of racial or ethnic group. We also found that there were no differences in the frequency of relapse by race and ethnicity, and that about half of patients relapse, regardless of race or ethnicity.”

Umaretiya and her team also observed no difference in OS rural vs urban areas.

Investigators will next examine the interaction of survival and race, ethnicity, and poverty, acknowledging the intersectionality of these factors due to structural racism in the United States. “Our data also suggests that even though we relapse occurs at the same frequency across racial and ethnic groups, the rates of death do not,” Umaretiya said. “Our next steps will focus on this post-relapse period and [we will] specifically look at enrollment on early phase trials as a proxy for access to life extending therapy as well as the causes of death, looking at whether these children die of disease or toxicity.”

ASCO President Everett E. Vokes, MD, chair of the department of medicine at the University of Chicago and the 2013 Giants of Cancer Care® award winner for head and neck cancer, said that children in these trials should have had similar outcomes and that they did not raises important questions.

“We see discrepancies here in OS … of 8% to 10% at the longer terms of follow up,” he said. “They seem to correlate with socioeconomic factors and race, but the specific causes of death, or increased death, in those groups are not elucidated yet. And I think that that will be important work moving forward.”


  1. Umaretiya P, Naranjo A, Zhang F, et al. Racial, ethnic, and socioeconomic survival disparities among children with high-risk neuroblastoma treated on upfront Children’s Oncology Group clinical trials. Presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL. Abstract 10005.
  2. Race, ethnicity and poverty associated with lower overall survival in children with high-risk neuroblastoma. News release. May 26, 2022. Accessed May 26, 2022. https://bit.ly/3GmlctL
Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.